New migraine drug offers hope for Triptan-Resistant patients
NCT ID NCT07685769
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests the safety and tolerability of rimegepant 75 mg ODT for acute migraine treatment in adults in India who have had an insufficient response, intolerance, or contraindication to triptans. About 60 participants take the drug as needed at the start of a migraine attack. The study monitors side effects and treatment satisfaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rimegepant 75 mg orally disintegrating tablet (ODT)
- What this could lead to
- If successful, this could provide a new acute treatment option for migraine patients who cannot use or do not respond to triptans.
- What could go wrong
- This is a small, open-label Phase 4 study with no placebo group, so results may be less reliable. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE TREATMENT OF MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.